These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28954991)

  • 1. Antiangiogenic agent sunitinib induces epithelial to mesenchymal transition and accelerates motility of colorectal cancer cells.
    Tomida C; Yamagishi N; Nagano H; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    J Med Invest; 2017; 64(3.4):250-254. PubMed ID: 28954991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells.
    Tomida C; Yamagishi N; Nagano H; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    Int J Oncol; 2018 Apr; 52(4):1350-1362. PubMed ID: 29532881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib induces adaptive resistance of colorectal cancer cells via inhibition of vascular endothelial growth factor receptor.
    Tomida C; Nagano H; Yamagishi N; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    J Med Invest; 2017; 64(3.4):262-265. PubMed ID: 28954993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic exposure of VEGF inhibitors promotes the malignant phenotype of colorectal cancer cells.
    Tomida C; Yamagishi N; Aibara K; Yano C; Uchida T; Abe T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    J Med Invest; 2015; 62(1-2):75-9. PubMed ID: 25817288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
    Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
    Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
    Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
    Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways.
    Aita Y; Ishii KA; Saito Y; Ikeda T; Kawakami Y; Shimano H; Hara H; Takekoshi K
    Am J Physiol Endocrinol Metab; 2012 Oct; 303(8):E1006-14. PubMed ID: 22912364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of chronic stress on anti-angiogenesis of sunitinib in colorectal cancer models.
    Liu J; Deng GH; Zhang J; Wang Y; Xia XY; Luo XM; Deng YT; He SS; Mao YY; Peng XC; Wei YQ; Jiang Y
    Psychoneuroendocrinology; 2015 Feb; 52():130-42. PubMed ID: 25437118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
    Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
    Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.
    Nguyen L; Fifis T; Christophi C
    BMC Cancer; 2016 Jul; 16():533. PubMed ID: 27460820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib, a small-molecule receptor tyrosine kinase inhibitor, suppresses neointimal hyperplasia in balloon-injured rat carotid artery.
    Ishii S; Okamoto Y; Katsumata H; Egawa S; Yamanaka D; Fukushima M; Minami S
    J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):359-66. PubMed ID: 23324994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
    Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
    Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts.
    Gaustad JV; Simonsen TG; Andersen LMK; Rofstad EK
    BMC Cancer; 2017 Jun; 17(1):411. PubMed ID: 28606060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
    BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
    Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
    Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The malignant progression effects of regorafenib in human colon cancer cells.
    Tomida C; Aibara K; Yamagishi N; Yano C; Nagano H; Abe T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    J Med Invest; 2015; 62(3-4):195-8. PubMed ID: 26399347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels.
    Osusky KL; Hallahan DE; Fu A; Ye F; Shyr Y; Geng L
    Angiogenesis; 2004; 7(3):225-33. PubMed ID: 15609077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines.
    Mizumoto A; Yamamoto K; Nakayama Y; Takara K; Nakagawa T; Hirano T; Hirai M
    J Pharmacol Exp Ther; 2015 Nov; 355(2):152-8. PubMed ID: 26306766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.